Reports not available

As an adjunct to diet and excercise for treatment of Obese patients.

Rimonabant treatment showed an excellant tolerance among patients except for some mild gastrointestinal adverse effects at the highest dose administered

Safety data from preliminary results of the RIO- Lipids, RIO -Europe, and RIO-America - trials revealed that Rimonabant is well tolerated aming patients efects

Most frequently reported adverse  effects are- Dizziness, Upper respiratory Infections

Diarrhoea was seen most commonly in the RIO- Europe tria ( 2.%, 5.5% and 7.8% for placebo Roimonabant 5mg//day and 20mg /day respy.

Side effects were mild, transient, self-limiting and occured early in the treatment period.

The most important side effects included nausea, dizzines, diarrhoea, vomiting, self reported hypoglycemia, fatigue and anxiety.

Dosage- 20mg/day

Chemistry- Rimonabant is a neurokinin - 3 antagonist and selective cannabinoid CBI receptor antagonist currently being reseached and deveoped. The Chemical name- N-piperino5 -(4 chlorophenyl) - 1 -(2,4-dichlorophenyl ) -4 -methyl pyrazole -3 carboxamide Mechanism of Action- Rimonabant is te first in a new class of agents that act by selectively blocking the cannabinoid -1 receptors with resultant central and metabolic peripheral effects, therby decreasing food intake and increases energy expenditure CB1 receptors are present both in the cNS as well as in certain peripheral tissues like adipocytes, gastointestinal tract and liver. Rimonabant is reported to possess a 1000- fold affinity for CB1 receptor than CB2 receptor.

Pharmacokinetics-

Rimonabant has demonstrated a long duration of action ( 8 hours) and good oral bioavailability Rimonabant is able to antagonise the pharmacologic effects induced by cannabinoid receptor agonists. It powerfully reduces food intake and increases energy expenditure It modulates the rewarding properties of food by inhibiting the action of endogenous cannabinoids at specific mesolimbic areas. It alters the variety of signals of peripheral origin ( leptin, ghrelin, and adiponectin) which modulate the neurochemical activation of hypthalamic neurons and the stae of relative balance. Rimonabant also inhibits the enzymes involved in lipogenesis.

It powerfully reduces food intake and increases energy expenditure It modulates the rewarding properties of food by inhibiting the action of endogenous cannabinoids at specific mesolimbic areas.

Reports not available